Trials / Completed
CompletedNCT00037206
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis.
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The combination of Anidulafungin plus AmBisome® may offer an improved outcome for patients treated for Invasive Aspergillosis (IA). The purpose of this study is to determine the safety and the clinical and microbiological effectiveness of anidulafungin plus AmBisome® in treated patients located in the United States, Europe, and South Africa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anidulafungin, VER002 |
Timeline
- Start date
- 2002-05-01
- Completion
- 2003-02-01
- First posted
- 2002-05-17
- Last updated
- 2008-10-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00037206. Inclusion in this directory is not an endorsement.